Key result
New AF during dobutamine stress echocardiography is linked to a ~4-fold increase in all-cause mortality.
Why the study?
Atrial fibrillation uncommonly occurs during dobutamine stress echocardiography and its predictors and long-term prognostic significance were not well characterized.
Does the development of atrial fibrillation during dobutamine stress echocardiography predict adverse long-term clinical outcomes?
Observational (n=217)
Does the development of atrial fibrillation during dobutamine stress echocardiography predict adverse long-term clinical outcomes?
Development of atrial fibrillation during dobutamine stress echocardiography is associated with underlying structural heart disease and predicts a significantly higher risk of long-term adverse cardiovascular events and mortality.
AIMS: Atrial fibrillation (AF) uncommonly occurs during dobutamine stress echocardiography (DSE). We aimed to characterize the predictors and long-term prognostic significance of AF during DSE. METHODS: The clinical, echocardiographic, and outcome data of patients in sinus rhythm who developed AF during DSE were reviewed and compared to a propensity score-matched group of controls. RESULTS: Atrial fibrillation developed in 73 (1% of 7026) patients (age 70±10 years, 58% men). Compared to 144 propensity score-matched controls without AF during DSE, those with AF were more likely to have had history of prior AF (23% vs 8%, P=.002), known coronary artery disease (CAD; 22% vs 10%, P=.037), enlarged left ventricle (LV; 27% vs 9%, P=.002), LV wall-motion abnormality (33% vs 12%, P<.0001), enlarged aortic root (22% vs 8%, P=.009), or dilated left atrium (52% vs 30%, P=.002). Multivariate logistic regression analysis identified prior history of AF (OR=3.7, 95% CI 1.5-9.0, P=.005), larger LV size (OR=3.1, 95% CI 1.3-7.3, P=.009), and lower LV ejection fraction (OR=-0.95, 95% CI -0.92 to -0.99, P=.02) as independent predictors of AF during DSE. At a mean follow-up period of 3.4 (0.5-7.3) years, those with AF during DSE were more likely to develop new coronary events (22% vs 10%, P=.0372), new-onset heart failure (19% vs 4%, P=.0003), or die from any cause (27% vs 6%, P<.0001). Kaplan-Meier curves demonstrated significantly lower event-free survival in patients compared to controls (P by log-rank test=.001) over the follow-up period. CONCLUSION: Dobutamine-induced AF occurs more commonly in those with prior history of AF and remodeled LV and is associated with unfavorable outcomes.
No takes yet. Share an insight, caveat, or question.
Acharya et al. (2017) conducted an observational in Patients undergoing dobutamine stress echocardiography (n=217). Atrial fibrillation during dobutamine stress echocardiography vs. No atrial fibrillation during dobutamine stress echocardiography was evaluated on All-cause mortality (p=<.0001). Development of atrial fibrillation during dobutamine stress echocardiography was associated with higher all-cause mortality (27% vs 6%, P<.0001) compared to matched controls over 3.4 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: